Animal PET for thioacetamide-induced rat cholangiocarcinoma: A novel and reliable platform

Molecular Imaging and Biology

Volumn 10, Issue 4, 2008, Pages 209-216

  Yeh, Chun Nan ^a   Lin, Kun Ju ^a,b   Hsiao, Ing Tsung ^a,b   Yen, Tzu Chen ^b   Chen, Tsung Wen ^a   Jan, Yi Yin ^a   Chung, Yi Hsiu ^a   Lin, Chung Fu ^a   Chen, Miin Fu ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Animal PET; Cholangiocarcinoma; FDG; Thioacetamide

Indexed keywords

ACETIC ACID C 11; FLUORODEOXYGLUCOSE F 18; THIOACETAMIDE; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTORADIOGRAPHY; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG UPTAKE; EX VIVO STUDY; FEASIBILITY STUDY; HISTOPATHOLOGY; IMAGE ANALYSIS; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RELIABILITY; SENSITIVITY AND SPECIFICITY; SPRAGUE DAWLEY RAT;

ACETATES; ANIMALS; AUTORADIOGRAPHY; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARBON RADIOISOTOPES; CARCINOGENS; CHOLANGIOCARCINOMA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEASIBILITY STUDIES; FLUORODEOXYGLUCOSE F18; MALE; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; THIOACETAMIDE; TIME FACTORS;

ANIMALIA; RATTUS;

EID: 45849092216     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-008-0141-8     Document Type: Article

References (37)

1. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368-1378
2. Ahrendt SA, Nakeeb A, Pitt HA (2001) Cholangiocarcinoma. Clin Liver Dis 5:191-218
3. bores-Saavedra J, Henson DE, Sobin LH (1992) The WHO histological classification of tumors of the gallbladder and extrahepatic bile ducts. A commentary on the second edition. Cancer 70:410-414
4. Fleming KA, Boberg KM, Glaumann H et al (2001) Biliary dysplasia as a marker of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 34:360-365
5. Hansel DE, Rahman A, Hidalgo M et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163:217-229
6. Terada T, Nakanuma Y, Sirica AE (1998) Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 29:175-180
7. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE (2002) ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 36:439-450
8. Villa R, Gornati D, Zaffaroni N et al (1997) Comparative in vitro sensitivity of human cholangiocarcinoma and colon adenocarcinoma cells to anticancer agents. Anticancer Res 17:961-968
9. Hudd C, Euhus DM, LaRegina MC et al (1985) Effect of cholecystokinin on human cholangiocarcinoma xenografted into nude mice. Cancer Res 45:1372-1377
10. Sirica AE (2005) Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 41:5-15
11. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF (2004) Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: An animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 25:631-636
12. Kelloff GJ, Hoffman JM, Johnson B et al (2005) Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 11:2785-2808
13. Keiding S, Hansen SB, Rasmussen HH et al (1998) Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 28:700-706
14. Ho CL, Yu SC, Yeung DW (2003) 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 44:213-221
15. Oyama N, Akino H, Kanamaru H et al (2002) 11C-acetate PET imaging of prostate cancer. J Nucl Med 43:181-186
16. Ho CL, Chen S, Yeung DW, Cheng TK (2007) Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 48:902-909
17. Laverman P, Blokx WA, Te Morsche RH et al (2007) [(18)F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. Hepatol Res 37:127-132
18. Ishiwata K, Ishii S, Senda M (2005) Successive preparation of C-11 labeled sodium acetate and/or sodium hexanoate. Appl Radiat Isot 46:1035-1037
19. Fuchtner F, Steinbach J, Mading P, Johannsen B (1996) Basic hydrolysis of 2-[F-18]fluoro-1,3,4,6-tetra-O-acetyl-d-glucose in the preparation of 2-[F-18]fluoro-2-dexoy-d-glucose. Appl Radiat Isot 47:61-66
20. Lin KJ, Yen TC, Wey SP et al (2004) Characterization of the binding sites for 123I-ADAM and the relationship to the serotonin transporter in rat and mouse brains using quantitative autoradiography. J Nucl Med 45:673-681
21. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35:1773-1782
22. Jan YY, Yeh TS, Yeh JN, Yang HR, Chen MF (2004) Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: Appraisal of an animal model of cholangiocarcinoma. Ann Surg 240:89-94
23. Cherry SR, Gambhir SS (2001) Use of positron emission tomography in animal research. ILAR J 42:219-232
24. Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD (2003) Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 30:1467-1472
25. Fritscher-Ravens A, Bohuslavizki KH, Broering DC et al (2001) FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 22:1277-1285
26. Salem N, MacLennan GT, Kuang Y et al (2007) Quantitative evaluation of 2-deoxy-2[F-18]fluoro-d-glucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol 9:135-143
27. Lee JD, Yang WI, Park YN et al (2005) Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18)F-FDG uptake. J Nucl Med 46:1753-1759
28. Kondo S, Hosono MN, Wada Y et al (2004) Use of FDG-microPET for detection of small nodules in a rabbit model of pulmonary metastatic cancer. Ann Nucl Med 18:51-57
29. Jadvar H, Henderson RW, Conti PS (2007) [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: Computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 31:223-228
30. Ishiwata K, Liu HY, Teramoto K et al (2006) Tumor viability evaluation by positron emission tomography with [18F]FDG in the liver metastasis rat model. Ann Nucl Med 20:463-469
31. Yao R, Seidel J, Johnson CA et al (2000) Performance characteristics of the 3-D OSEM algorithm in the reconstruction of small animal PET images. Ordered-subsets expectation-maximization. IEEE Trans Med Imaging 19:798-804
32. Teo BK, Seo Y, Bacharach SL et al (2007) Partial-volume correction in pet: Validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med 48:802-810
33. Keiding S, Munk OL, Schiott KM, Hansen SB (2000) Dynamic 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography of liver tumours without blood sampling. Eur J Nucl Med 27:407-412
34. Hong D, Lunagomez S, Kim EE et al (2005) Value of baseline positron emission tomography for predicting overall survival in patient with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104:1620-1626
35. Stumpe KD, Dazzi H, Schaffner A, von Schulthess GK (2000) Infection imaging using whole-body FDG-PET. Eur J Nucl Med 27:822-832
36. Tietge UJ, Selberg O, Kreter A et al (2004) Alterations in glucose metabolism associated with liver cirrhosis persist in the clinically stable long-term course after liver transplantation. Liver Transpl 10:1030-1040
37. Hamazawa Y, Koyama K, Okamura T et al (2007) Comparison of dynamic FDG-microPET study in a rabbit turpentine-induced inflammatory model and in a rabbit VX2 tumor model. Ann Nucl Med 21:47-55